Figure 3.
Figure 3. Increased classical monocytes in NUP98-HBO1 BMT mice. (A) Flow cytometric analysis of CD115/Ly6C expression in PB WBCs from the control and NUP98-HBO1 BMT mice at 8 to 10 weeks after transplantation. (B) Percentage of monocytes (CD115+) and neutrophils (CD115− Ly6Cdim) in PB WBCs from the control and NUP98-HBO1 BMT mice. (C) Percentage of inflammatory monocytes (CD115+ Ly6Chigh) in PB monocytes from the control and NUP98-HBO1 BMT mice. (D) Flow cytometric analysis of Gr1/CD115 expression in BM cells from the control at 8 to 10 weeks after BMT and moribund NUP98-HBO1 BMT mice. (E) Percentage of granulocytes (CD115− Gr1high) and monocytes (CD115+) in BM from the control and NUP98-HBO1 BMT mice. (F) Flow cytometric analysis of c-Kit/CD115 expression in BM cells from the control and NUP98-HBO1 BMT mice. (G) Percentage of c-Kit+ immature cells in BM from the control and NUP98-HBO1 BMT mice. Throughout, n = 5 per group; data are presented as mean ± SD. **P < .01, ***P < .001, ****P < .0001. NS, not significant.

Increased classical monocytes in NUP98-HBO1 BMT mice. (A) Flow cytometric analysis of CD115/Ly6C expression in PB WBCs from the control and NUP98-HBO1 BMT mice at 8 to 10 weeks after transplantation. (B) Percentage of monocytes (CD115+) and neutrophils (CD115 Ly6Cdim) in PB WBCs from the control and NUP98-HBO1 BMT mice. (C) Percentage of inflammatory monocytes (CD115+ Ly6Chigh) in PB monocytes from the control and NUP98-HBO1 BMT mice. (D) Flow cytometric analysis of Gr1/CD115 expression in BM cells from the control at 8 to 10 weeks after BMT and moribund NUP98-HBO1 BMT mice. (E) Percentage of granulocytes (CD115 Gr1high) and monocytes (CD115+) in BM from the control and NUP98-HBO1 BMT mice. (F) Flow cytometric analysis of c-Kit/CD115 expression in BM cells from the control and NUP98-HBO1 BMT mice. (G) Percentage of c-Kit+ immature cells in BM from the control and NUP98-HBO1 BMT mice. Throughout, n = 5 per group; data are presented as mean ± SD. **P < .01, ***P < .001, ****P < .0001. NS, not significant.

Close Modal

or Create an Account

Close Modal
Close Modal